Will the Spanish multinational HIPRA's Covid-19 vaccine pass the European Medicines Agency (EMA) test?
The answer so far seems positive.
As the regulator announced the launch of the serum review process on Tuesday, it said “preliminary results suggest that the immune response to the Spanish HIPRA vaccine may be effective against SARS-CoV-2, including variants that are of concern such as Omicron”.
The Agency, whose headquarters are in Amsterdam, did not specify how long the study procedure for this first Spanish vaccine, called PHH-1V, would take.
Under European law, HIPRA must obtain approval from the EMA before it can apply for the marketing of its vaccine in the 27 countries of the European Union.
A vaccine “which prepares the body to defend itself”
PHH-1V is based on the process of recombinant proteins, a formula also used by the American company Novavax and the partnership between the French laboratory Sanofi and the British GSK.
It is a vaccine “which prepares the body to defend itself” against Covid-19, writes the EMA.
It combines two specific types of proteins used by the coronavirus to enter host cells in the human body.
To date, the EMA has approved the use of five vaccines within the European Union: messenger RNA vaccines from the American groups Pfizer and Moderna, those from the Swedish-British laboratory AstraZeneca and its American competitor Johnson & Johnson , which use a viral vector, and the Novavax vaccine.
Covid-19: Contaminations and critical care admissions on the rise
Covid-19: Does the obligation to vaccinate caregivers, which have become a campaign topic, still make sense?
Share on Messenger
Share on Facebook
Share on Twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
A fault ?